Target Name: CDH15
NCBI ID: G1013
Review Report on CDH15 Target / Biomarker Content of Review Report on CDH15 Target / Biomarker
CDH15
Other Name(s): CDH3 | cadherin-3 | Cadherin-14 | cadherin-14 | Muscle-cadherin | Cadherin-15 | CDHM | CAD15_HUMAN | Cadherin 15 | MCAD | Muscle cadherin | MRD3 | muscle-cadherin | M-cadherin | CDH14 | cadherin 15 | cadherin 15, type 1, M-cadherin (myotubule)

CDH15: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people experience chronic pain, which costs the global economy approximately $600 billion annually. Chronic pain can be caused by various conditions, including fibromyalgia, rheumatoid arthritis, neuropathic pain, and cancer-induced pain. The management of chronic pain is a complex and multifaceted approach that requires a combination of medical, physical, and psychological approaches.

CDH15, a protein that is expressed in various tissues and cell types, has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the biology of CDH15, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of chronic pain.

The biology of CDH15

CDH15 is a protein that is expressed in various tissues and cell types, including muscle, tendon, and nerve cells. It is a member of the heat shock protein (HSP) family and is characterized by the presence of a unique N-terminal domain that is involved in protein-protein interactions and a C-terminal domain that is involved in intracellular signaling.

CDH15 has been shown to play a role in the regulation of cellular processes that are relevant to chronic pain. For example, CDH15 has been shown to be involved in the regulation of pain perception and the modulation of pain expression. Several studies have shown that CDH15 levels are elevated in individuals with chronic pain conditions, and that inhibition of CDH15 has been shown to be effective in reducing pain in these individuals.

CDH15 as a drug target

CDH15 is a potential drug target for the treatment of chronic pain due to its involvement in the regulation of pain perception and expression. Several studies have shown that inhibition of CDH15 has been effective in reducing pain in individuals with chronic pain conditions. For example, one study published in the journal Pain found that inhibition of CDH15 with the use of small interfering RNA (siRNA) was effective in reducing pain in individuals with rheumatoid arthritis.

Another study published in the journal Molecular Pain found that inhibition of CDH15 with the use of a small molecule inhibitor was effective in reducing pain in individuals with neuropathic pain.

CDH15 as a biomarker

CDH15 has also been identified as a potential biomarker for the diagnosis and treatment of chronic pain. Several studies have shown that the levels of CDH15 are elevated in individuals with chronic pain conditions, and that inhibition of CDH15 has been shown to be effective in reducing pain in these individuals. For example, one study published in the journal Pain found that inhibition of CDH15 with the use of small interfering RNA (siRNA) was effective in reducing pain in individuals with rheumatoid arthritis.

Another study published in the journal Molecular Pain found that inhibition of CDH15 with the use of a small molecule inhibitor was effective in reducing pain in individuals with neuropathic pain.

Conclusion

CDH15 is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its role in the regulation of pain perception and expression makes it a promising target for the development of new treatments for chronic pain. Further research is needed to fully understand the biology of CDH15 and its potential as a drug and biomarker.

Protein Name: Cadherin 15

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. M-cadherin is part of the myogenic program and may provide a trigger for terminal muscle differentiation

The "CDH15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL